Inventive Programs, Products and Collaborations Take Center Stage at Annual Event
SAN RAMON, Calif., January 22, 2020—Following a banner year that saw CooperVision garner groundbreaking product approvals, acquire new technologies, expand its brand families and deepen relationships with eye care professionals (ECPs), the company is poised for additional advancements in 2020. Attendees at the annual Global Specialty Lens Symposium (GSLS) from January 22 – 25 will experience this momentum first-hand through multiple CooperVision events and exhibits.
“Some may view 2020 as a culmination of efforts to move eyecare forward, but CooperVision has a different perspective,” said Jerry Warner, Executive Vice President, Americas and Global Commercial Functions. “It’s a milestone year that marks the beginning of so much to come for myopia and specialty eyecare, thanks to inventive technologies, differentiated programs, and a shared commitment to elevating the profession and practice. We’re excited about what’s ahead and look forward to sharing more during GSLS.”
Visionary Products and Programs
For the first time in a public setting, CooperVision will discuss its Brilliant Futures™ Myopia Management Program, which seeks to create a new standard of care for children with myopia. Based on a comprehensive approach with CooperVision MiSight® 1 day contact lenses as its cornerstone, it provides inclusive practice, child and parent support. The result is the optimal environment for compliance, satisfaction, clinical outcomes and long-term loyalty. The Brilliant Futures™ Myopia Management Program is expected to be available in the United States beginning in March.
MiSight® 1 day lenses are expected to be available in the United States beginning in March. They are the first and only U.S. Food and Drug Administration-approved product1 to slow the progression of myopia when initially prescribed for children 8-12 years old* in the U.S.
“Our Brilliant Futures™ Myopia Management Program offers a new approach to address the rising severity and prevalence of myopia progression. Reaction during our preview event earlier this month was universally positive, citing the mix of care protocols, tools, education and support we’ll be offering in partnership with ECPs,” said Michele Andrews, OD, Senior Director of North America Professional & Academic Affairs at CooperVision.
Blanchard’s flagship Onefit Scleral Lens Platform is also making strides with expanded design options, including their latest scleral lens design Onefit™ MED+, which offers a larger diameter for OSD, Post-Surgical, Dry Eye and highly irregular cornea applications. The Onefit family of scleral lenses provide crystal clear vision in a reliable and comfortable lens to a wide variety of patients. This includes athletes who require lenses that won’t pop out, while providing protection against wind, dust and debris, as is demonstrated by Onefit brand ambassador Kim Boutin - a Canadian short track speedskater, who has earned multiple gold medals this season while wearing Blanchard’s Onefit MED scleral lenses
Orthokeratology contact lenses like Paragon CRT® have been proven to improve patients’ quality of life, from the extreme athletes like X Games and Olympic-bound skateboarder Trey Woods—the product’s newest brand ambassador—to everyday kids and adults.2 In addition to demonstrating new practitioner tools that make it easier than ever to fit and market the lenses, the company will announce Paragon CRT® updates available later this year.
Education and Sound Science
As GSLS opens, CooperVision will again host its popular Educator’s Meeting. The half-day workshop brings together administrators and faculty from nearly two dozen schools and colleges of optometry in the United States and Canada to catalyze closer peer-to-peer relationships, consider the impact of new technologies and approaches on curricula, and examine the future of the profession and the next generation of ECPs.
Over the course of the four-day conference, the company will also deliver seven educational sessions. Topics include children and contact lenses, the Onefit Med+ and Paragon CRT platforms, interpreting efficacies in clinical myopia control studies, integrating myopia management into practice, and outcomes from the landmark MiSight® 1 day three-year clinical study.
The latest data from the multi-year MiSight® 1 day initiative will also be shared in greater depth as part of the GSLS scientific poster sessions. Five-year outcomes are the subject of a display exhibited from 1:30 – 4 pm PDT on Thursday, January 23 and once again from 10 – 11 a.m. PDT on Saturday, January 25.
“We have built our reputation through inventive approaches to some of the greatest challenges in eye care, combining advanced technologies with a highly collaborative approach alongside ECPs, researchers and educators. What we’re doing at GSLS 2020 signals more to come, and we couldn’t be more enthusiastic,” said Warner.
# # #
MiSight® 1 day contact lenses are currently approved for sale in the United States, Canada, the United Kingdom, France, Spain, Portugal, Netherlands, Belgium, Germany, Austria, Switzerland, the Nordic Region, Italy, Singapore, Malaysia, Hong Kong, Australia and New Zealand.
1 Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
* when compared to the children in the control group wearing a single vision 1-day contact lens.
2 F. Z., G. Z., & Z. Z. (2018). Investigation of the Effect of Orthokeratology Lenses on Quality of Life and Behaviors of Children. Contact Lens Association of Ophthalmologists, Inc., 44(5). Retrieved May 8, 2019.
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of daily disposable, two-week and monthly contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism, presbyopia and childhood myopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Mike McDougall, APR, Fellow PRSA
McDougall Communications for CooperVision
+1-585-545-1815 or email@example.com